Tempus AI (NASDAQ:TEM) Price Target Raised to $80.00

Tempus AI (NASDAQ:TEM) had its target price increased by BTIG Research from $70.00 to $80.00 in a report released on Thursday morning, MarketBeat.com reports. BTIG Research currently has a buy rating on the stock.

A number of other research analysts have also weighed in on TEM. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Finally, Stifel Nicolaus cut their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $65.69.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $72.69 on Thursday. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI has a twelve month low of $40.77 and a twelve month high of $104.32. The stock’s 50 day moving average is $52.93 and its 200-day moving average is $51.36. The firm has a market capitalization of $13.12 billion, a price-to-earnings ratio of -50.48 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period last year, the business earned ($0.22) EPS. Sell-side analysts forecast that Tempus AI will post -1.38 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In related news, CFO James William Rogers sold 26,313 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the transaction, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the transaction, the chief executive officer owned 562,463 shares in the company, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 943,202 shares of company stock worth $46,417,587. 24.26% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. grew its holdings in shares of Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after acquiring an additional 162 shares in the last quarter. Truist Financial Corp lifted its holdings in Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares during the period. Farther Finance Advisors LLC boosted its position in Tempus AI by 3.5% in the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock worth $377,000 after purchasing an additional 219 shares during the last quarter. SeaCrest Wealth Management LLC boosted its position in Tempus AI by 3.7% in the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock worth $524,000 after purchasing an additional 229 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in Tempus AI by 29.4% in the 4th quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock valued at $65,000 after purchasing an additional 250 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.